ClinicalTrials.gg
TerminatedNCT04566926AMPARUpdated Apr 27, 2025

A Study of JNJ-64140284 in Healthy Male Participants

A Phase 1 interventional study of JNJ-64140284 and Placebo in Healthy, sponsored by Janssen Pharmaceutica N.V., Belgium. Terminated at 1 site in Belgium. Open to male participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Phase 1, Interventional, and Other

How we know

Why this study was terminated
business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
Male
01

Study summary

The purpose of the study is to investigate and compare the pharmacokinetic (PK) profiles of a single dose of two solid dosage formulations of JNJ-64140284 in plasma and urine in healthy male participants under fed and fasting conditions; and to investigate the safety and tolerability of two solid dosage formulations of JNJ 64140284 versus placebo after single oral dose administration in healthy male participants under fed and fasting conditions in Part 1; to investigate the safety and tolerability of JNJ-64140284 versus placebo after single oral dose administration (or 1 divided dose, if applicable) (ascending dose levels) in healthy male participants; and to characterize the PK of a single dose (or 1 divided dose, if applicable) of JNJ-64140284 in plasma in healthy male participants in Part 2; and to investigate the effect of food on the PK of a single (or 1 divided dose, if applicable) therapeutic relevant dose of JNJ 64140284 in healthy male participants; and to investigate the safety and tolerability of JNJ-64140284 versus placebo after single oral dose administration at a therapeutic relevant dose (or 1 divided dose, if applicable) in fed conditions in Part 3.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Pharmaceutica N.V., Belgium is the lead sponsor of 58 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a (BMI) between 18.0 and 29.9 kilograms per square meters (kg/m\^2) inclusive
  • Participant must be healthy on the basis of clinical laboratory tests. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, retesting of an abnormal lab value(s) that may lead to exclusion will be allowed. The participant may be included only if the investigator judges the abnormalities or deviations from normal to be not or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Participant must be healthy on the basis of physical and neurological examination, medical history, vital signs, and 12-lead (ECG) (means of triplicate ECG, incl. less than or equal to [\<=] 450 milliseconds [msec] for males). Minor abnormalities in ECG, which are not considered to be of clinical significance by the investigator, are acceptable
  • A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person and must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 3 months after receiving the last dose of study intervention
  • Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol

Exclusion criteria

Exclusion criteria:

  • Participant has history of or current significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematological disease, lipid abnormalities, bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, Parkinson's disease, infection, or any other illness that the Investigator considers should exclude the participant
  • Participant has a Left Bundle Branch Block (LBBB), atrioventricular (AV) Block (second degree or higher), or a permanent pacemaker or implantable cardioverter defibrillator (ICD)
  • Participant has a history of suicidal ideation or a family history of suicide
  • Participant has a history of major depressive disorder or bipolar disorder according to (5th edition) (DSM-V) criteria
  • Participant has a history of surface antigen (HBsAg) or antibody (anti HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti HCV at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1 (Placebo or JNJ-64140284)

    Participants will receive matching placebo in Treatment A or JNJ-64140284 (as formulation 1) in Treatment B or JNJ-64140284 (as formulation 2) in Treatment C on Day 1 under fasted condition. Participants will receive treatment in either of the 6 treatment sequences (ABC, BCA, CAB, CBA, ACB or BAC) in Period 1, 2, or 3 under fasted condition. Each period is separated by washout period of 5 days.

    Drug: JNJ-64140284 · Drug: Placebo

  • Experimental
    Part 1: Cohort 2 (Placebo or JNJ-64140284)

    Participants will receive matching placebo (Treatment D) or JNJ- 64140284 (as formulation 1) in Treatment E or JNJ-64140284 (as formulation 2) in Treatment F. Participants will receive treatment in either of 6 treatment sequence (DEF, EFD, FDE, FED, DFE or EDF) in Period 1, 2, or 3 under fed condition. Each period is separated by washout period of 5 days.

    Drug: JNJ-64140284 · Drug: Placebo

  • Experimental
    Part 2: Cohorts 1-7 (JNJ-64140284 or Placebo)

    Participants will receive JNJ 64140284 formulation 1 or 2 or matching placebo under fasting condition in Cohorts 1 to 7 on Day 1.

    Drug: JNJ-64140284 · Drug: Placebo

  • Experimental
    Part 3: Cohorts 1-2 (JNJ-64140284 or placebo)

    Participants will receive JNJ-64140284 formulation 1 or 2 or matching placebo under fed condition in Cohorts 1 to 2 on Day 1.

    Drug: JNJ-64140284 · Drug: Placebo

Interventions

  • Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.

  • DrugPlacebo

    Participant will receive matching placebo.

06

What researchers measure

Primary outcomes

  1. Part 1: Plasma Concentration of JNJ-64140284

    Plasma samples will be analyzed to determine concentrations of JNJ-64140284 under fed and fasting conditions using a validated, specific and sensitive liquid chromatography-mass spectrometry (LC-MS/MS).

    Time frame: Pre-dose, Day 1, 2, 3 and Day 4

  2. Part 1: Urine Concentration of JNJ-64140284

    Urine samples will be analyzed to determine concentrations of JNJ-64140284 in renal clearance.

    Time frame: Pre-dose, Day 1, 2, 3 and Day 4

  3. Part 2: Plasma Concentration After Single Dose Administration of JNJ-64140284

    Plasma samples will be analyzed to determine concentrations of JNJ-64140284 under fed and fasting conditions using a validated, specific and sensitive liquid chromatography-mass spectrometry (LC-MS/MS).

    Time frame: Pre-dose, Day 1, 2, 3 and Day 4

  4. Part 3: Ratio of Area Under Plasma Concentration Curve (AUC) and Maximum Plasma Concentration (Cmax)

    Ratio of geometric means for pharmacokinetics (PK) parameters (AUCs and Cmax) of JNJ 64140284 (fed versus fasted condition) will be analyzed to determine the food effect.

    Time frame: Pre-dose, Day 1, 2, 3 and Day 4

  5. Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability: Part 1, Part 2, and Part 3

    An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.

    Time frame: Up to 1.5 years

Secondary outcomes

  1. Bond & Lader Visual Analogue Scale (VAS) Score: Part 1 and Part 2

    The VAS is a participant rated scale, made up of 16 (items) pairs of alternative descriptors of mood and attention at either end of a 10-centimeter (cm) line. The item score ranges from 0 to 100, with a high score reflecting a high level of anxiety, sedation or dysphoria.

    Time frame: Day -1, 1, 2 and Day 3

  2. Karolinska Sleepiness Scale (KSS) Score: Part 1 and Part 2

    The KSS is a participant-reported assessment used to rate sleepiness on a scale of 1 to 9, ranging from 'extremely alert' (1) to 'very sleepy, great effort to keep awake, fighting sleep' (9).

    Time frame: Day -1, 1, 2 and Day 3

  3. Body Sway

    Body sway will be used to measure body movements, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, alcohol, and benzodiazepines. It will be measured either using a stabilometric platform or a pot string meter based on the Wright ataxiameter.

    Time frame: Day -1, 1, 2 and Day 3

  4. Part 2: Pharmacodynamics (PD) as Assessed by Cognitive Test Battery: Detection Task (DET)

    DET is a measure of psychomotor function. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.

    Time frame: Day -1, 1, 2 and Day 3

  5. Part 2: PD as Assessed by Cognitive Test Battery: Identification Task (IDN)

    IDN is a measure of attention. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.

    Time frame: Day -1, 1, 2 and Day 3

  6. Part 2: PD as Assessed by Cognitive Test Battery: One Card Learning Task (OCL)

    OCL is a measure of visual learning. The test measures accuracy of performance; arcsine transformation of the square root of the proportion of correct responses. Higher score indicates better performance.

    Time frame: Day -1, 1, 2 and Day 3

  7. Part 2: PD as Assessed by Cognitive Test Battery: One Back Task (ONB)

    ONB is a measure of working memory. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.

    Time frame: Day -1, 1, 2 and Day 3

  8. Part 2: PD as Assessed by Cognitive Test Battery: Groton Maze Learning Test (GMLT)

    GMLT is a measure of executive function and spatial learning. The test measures total number of errors made while locating and learning 28 step pathway hidden beneath a 10\*10 grid on 5 consecutive trials during a single session. Lower score indicates better performance.

    Time frame: Day -1, 1, 2 and Day 3

  9. Part 2: PD as Assessed by Cognitive Test Battery: International Shopping List Test (ISLT)

    The ISLT is a measure of verbal learning. The test measures total number of correct responses remembering the word list on 3 consecutive trials at a single assessment. Higher score indicates better performance.

    Time frame: Day -1, 1, 2 and Day 3

  10. Part 2: PD as Assessed by Cognitive Test Battery: International Shopping List Test delayed (ISLT-D)

    ISLT-D is a measure of delayed verbal memory. The test measures total number of correct responses recalling the word list learned initially. Higher score indicates better performance.

    Time frame: Day -1, 1, 2 and Day 3

  11. Part 2: PD as Assessed by Cognitive Test Battery: Groton Maze Learning Test delayed (GMLT-D)

    GMLT delayed recall is a measure of delayed spatial memory. The test measures number of errors made while locating 28 step pathway hidden beneath a 10\*10 grid after a delay. Lower score indicates better performance.

    Time frame: Day -1, 1, 2 and Day 3

07

Study locations

1 site
  • SGS Life Science Services
    Antwerpen, 2060, Belgium
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Apr 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Sep 28, 2020
StartActual
Sep 29, 2020
Primary completionActual
Apr 5, 2021
CompletionActual
Apr 5, 2021
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04566926
Responsible party
Sponsor
First posted
Sep 28, 2020
Start date
Sep 29, 2020
Primary completion
Apr 5, 2021
Completion
Apr 5, 2021
Last update
Apr 27, 2025

Study contacts

Janssen Pharmaceutica N.V., Belgium Clinical Trial
study director · Janssen Pharmaceutica N.V., Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JNJ-64140284

Start the discussion